ImmuneOncia Therapeutics KRX:424870KOSDAQ
이뮨온시아 · Korean news coverage and regulatory filings, organized.
Articles, 24h6
Articles, 7 days6
DART filings, 7 days2
Articles tracked6since Sep 11
In Q2 2026, ImmuneOncia Therapeutics reported revenue of ₩0m, down 100.0% year on year, and an operating loss of ₩4.3bn. ImmuneOncia Therapeutics (이뮨온시아) appeared in 6 Korean news articles and 2 DART filings over the past seven days. Coverage peaked on Sep 14 with 3 articles. The most common catalyst was clinical & approvals (2). It was most often mentioned alongside Xcell Therapeutics, Voronoi and Yuhan.
ImmuneOncia Therapeutics quarterly results separate, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩0m | -100.0% | −₩4.3bn | −₩3.9bn |
| Q1 2026 | ₩0m | -100.0% | −₩5.8bn | −₩5.6bn |
| Q4 2025 derived | ₩0m | -100.0% | −₩9.6bn | −₩9.4bn |
| Q3 2025 | – | – | −₩10.6bn | −₩10.4bn |
| Q2 2025 | ₩59m | – | −₩3.3bn | −₩3.1bn |
| Q1 2025 | ₩52m | – | −₩4.5bn | −₩4.4bn |
| Q4 2024 derived | ₩605m | – | −₩2.7bn | −₩2.6bn |
| Q3 2024 | ₩50m | – | −₩2.4bn | ₩4.0bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases.
ImmuneOncia Therapeutics top stories 2 weeks, by number of outlets
- 1
- 2
- 3
- 4
- 5
- 6
